This Guide is part of WHO’s overall programme of work on Political Economy of Health Financing Reform: Analysis and Strategy to Support UHC. The impetus for this work came from demands for more concrete evidence, recognition and integration of political economy issues within
health financing, and... overall system, reform design and implementation processes. This Guide is complementary to WHO’s Health Financing Progress Matrix assessment, as well as Health Financing Strategy development guidance. In this way, it promotes an embedded political
economy analysis approach that can be used in conjunction with other health financing assessments and guidance. The political economy framework can also be extended and easily adapted to broader health policy reforms.
more
2nd edition. This second edition builds on the experience of more than 10 years of SMC deployment, and reflects changes introduced in the WHO guidelines for malaria, 3 June 2022. The goal of this publication is to share these best practices to improve SMC implementation, coverage, and monitoring and... evaluation. Examples of materials and tools as well as links to resources are included to support managers and health workers in their efforts to conduct successful SMC activities and prevent malaria among vulnerable children.
more
Developed under the USAID-supported HRH2030 Capacity Building for Malaria (CBM) initiative, this guide offers a comprehensive framework for advising National Malaria Control Programmes (NMCPs) through the use of long-term technical advisors (LTTAs). It sets out key practices for implementing partner...s and advisors, covering advisor selection, onboarding, contextual analysis and capacity-building strategies at individual and organisational levels. It emphasises collaborative work planning, continuous performance monitoring, stakeholder engagement and the use of assessment tools such as the Capability Maturity Model (CMM) and the Organisational Development Assessment (ODA). The guide is designed to strengthen the leadership and operational effectiveness of NMCPs, promoting sustainable improvements in malaria control through structured mentorship, knowledge transfer and strategic partnerships.
more
2ieme edition. Ce guide présente un ensemble standardisé d'indicateurs pour le suivi et l'évaluation des programmes de communication pour le changement social et comportemental (CCS) ciblant la lutte contre le paludisme. Basée sur la première édition, publiée en 2014, cette deuxième édition... propose un ensemble plus rationalisé d'indicateurs prioritaires et inclut les prestataires de soins de santé comme public cible. Elle élargit également l'éventail des sources de données au-delà des enquêtes auprès des ménages
more
Le Plan stratégique national de plaidoyer en matière de lutte contre le paludisme (PSNPP) 2018-2023 servira à harmoniser la programmation des actions de plaidoyer et à garantir que les interventions de plaidoyer sont alignées sur les priorités du Plan stratégique national de lutte contre le p...aludisme (PSNP) 2016-2020. Il va guider
les professionnels du changement social et comportemental et de la communication en santé, et les autres parties prenantes concernées à concevoir, mettre en œuvre, surveiller et évaluer les interventions de plaidoyer pour s’assurer qu’elles sont compatibles avec les politiques nationales et internationales actuelles. Ce guide, développé à travers un processus stratégique qui prend en compte les principes d’une stratégie efficace, est localisé, ciblé, prouvé, collaboratif, influent, redevable et pérenne.
more
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
La Stratégie Nationale de Plaidoyer et de Mobilisation des Ressources en faveur de la Lutte contre le Paludisme 2024–2028 en République Démocratique du Congo vise à renforcer l’engagement politique, mobiliser des financements domestiques et internationaux et impliquer tous les secteurs (publ...ic, privé, société civile) pour réduire la mortalité liée au paludisme de 70 % et l’incidence de 50 % d’ici 2028.
Le document propose des actions concrètes : plaidoyer auprès des décideurs pour des budgets accrus, exonération des intrants antipaludiques, introduction du vaccin R21/Matrix-M, création de partenariats public-privé, implication des leaders communautaires et campagnes de sensibilisation via les médias. Il s’aligne sur la stratégie mondiale de l’OMS et promeut une approche multisectorielle, coordonnée par le Programme National de Lutte contre le Paludisme avec l’appui de partenaires comme l’USAID et Breakthrough ACTION.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more